Inventor · disambiguated record
Charlotte Mcdonagh
Also filed as: CARTER PAUL · MCDONAGH CHARLOTTE · MCDONAGH CHARLOTTE F · MCDONAGH CHARLOTTE FENTON
14 granted patents·23 pending applications·510 citations·filing 2002–2024
94Inventor score
Files withMAGENTA THERAPEUTICS INC8MCDONAGH CHARLOTTE8SEATTLE GENETICS INC7MERRIMACK PHARMACEUTICALS INC6SEAGEN INC3
Top patents by PatentIndex Score
37 records- 0198US8455622B2Variant target binding agents and uses thereofCARTER PAUL·Filed 2007·Granted Jun 4, 2013·120 cites·21 claims
- 0298US7968687B2CD19 binding agents and uses thereofSEATTLE GENETICS INC·Filed 2008·Granted Jun 28, 2011·139 cites·14 claims
- 0397US9701752B2Humanized anti-CD70 binding agents and uses thereofSEATTLE GENETICS INC·Filed 2016·Granted Jul 11, 2017·30 cites·25 claims
- 0497US8067546B2Humanized anti-CD70 binding agents and uses thereofMCDONAGH CHARLOTTE·Filed 2006·Granted Nov 29, 2011·71 cites·25 claims
- 0595US9919061B2CD19 binding agents and uses thereofSEATTLE GENETICS INC·Filed 2015·Granted Mar 20, 2018·9 cites·16 claims
- 0695US9428585B2Humanized anti-CD70 binding agents and uses thereofSEATTLE GENETICS INC·Filed 2013·Granted Aug 30, 2016·26 cites·31 claims
- 0795US8562987B2Humanized anti-CD70 binding agents and uses thereofMCDONAGH CHARLOTTE·Filed 2011·Granted Oct 22, 2013·27 cites·24 claims
- 0893US8242252B2CD19 binding agents and uses thereofMCDONAGH CHARLOTTE·Filed 2011·Granted Aug 14, 2012·29 cites·19 claims
- 0992US9073993B2CD19 binding agents and uses thereofMCDONAGH CHARLOTTE·Filed 2012·Granted Jul 7, 2015·10 cites·15 claims
- 1092US8927694B2Human serum albumin linkers and conjugates thereofMCDONAGH CHARLOTTE·Filed 2009·Granted Jan 6, 2015·27 cites·21 claims
- 1190US8257706B2CD30 binding agents and uses thereofMCDONAGH CHARLOTTE·Filed 2007·Granted Sep 4, 2012·20 cites·22 claims
- 1286US2024190981A1Humanized Anti-CD70 Binding Agents and Uses ThereofSEAGEN INC·Filed 2023·Application pending·0 cites
- 1382US9345766B2Combination therapies comprising anti-ERBB3 agentsMERRIMACK PHARMACEUTICALS INC·Filed 2013·Granted May 24, 2016·2 cites·5 claims
- 1479US2023033859A1Cd19 binding agents and uses thereofSEAGEN INC·Filed 2022·Application pending·0 cites
- 1576US12209135B2Anti-CD45 antibodies and conjugates thereofVOR BIOPHARMA INC·Filed 2024·Granted Jan 28, 2025·0 cites·22 claims
- 1673US2021002380A1Humanized Anti-CD70 Binding Agents and Uses ThereofSEATTLE GENETICS INC·Filed 2020·Application pending·0 cites
- 1768US11331394B2CD19 binding agents and uses thereofSEAGEN INC·Filed 2018·Granted May 17, 2022·0 cites·21 claims
- 1866US2024075157A1Fc silenced antibody drug conjugates (adcs) and uses thereofMAGENTA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1963US2017342157A1Humanized Anti-CD70 Binding Agents and Uses ThereofSEATTLE GENETICS INC·Filed 2017·Application pending·0 cites
- 2060US2015191545A1Human serum albumin linkers and conjugates thereofMERRIMACK PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 2157US2016326262A1Combination therapies comprising anti-erbb3 agentsMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 2256US2021283267A1Therapeutic methods using antibody drug conjugates (adcs)MAGENTA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2356US2018066065A1Combination therapies comprising anti-erbb3 agentsMERRIMACK PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 2454US2020376135A1Fc silenced antibody drug conjugates (adcs) and uses thereofMAGENTA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2553US2022175944A1Anti-cd117 antibody-drug conjugates and uses thereofMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2652US2022226493A1Anthracycline antibody-drug conjugates and uses thereofMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2752US2017204192A1Human serum albumin linkers and conjugates thereofMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 2851US2022175951A1Anti-CD45 Antibody Drug Conjugates and Uses ThereofMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2951US2015139936A1Dosage and administration of bispecific scfv conjugates in combination with anti-cancer therapeuticsMERRIMACK PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 3050US2022177577A1Anti-cd117 antibody drug conjugates and uses thereofMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3150US2006160174A1Modified l49-sfv exhibiting increased stability and methods of use thereofMCDONAGH CHARLOTTE F·Filed 2002·Application pending·0 cites
- 3249US2011059076A1Human serum albumin linkers and conjugates thereofMCDONAGH CHARLOTTE·Filed 2010·Application pending·0 cites
- 3346US2020255523A1Fc silenced antibody drug conjugates (adcs) and uses thereofMAGENTA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3443US2008305044A1Engineered Antibodies and ImmunoconjugatesSEATTLE GENETICS INC·Filed 2005·Application pending·0 cites
- 3543US2014017264A1Dosage and administration of bispecific scfv conjugatesMCDONAGH CHARLOTTE·Filed 2011·Application pending·0 cites
- 3638US2014056898A1Combination therapies comprising anti-erbb3 agentsZHANG BO·Filed 2012·Application pending·0 cites
- 3738US2015231238A1Overcoming resistance to erbb pathway inhibitorsGARCIA GABRIELA·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Charlotte Mcdonagh files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →